Perspective Therapeutics Inc. (CATX) is a Healthcare · Medical Devices company listed on NYSE MKT. Price $2.84 (-1.39%), Market cap $0.44B, 52-week low–high $2.05 ~ $5.65.
Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV
Financial statements, price targets, institutional (13F) holdings and related news for Perspective Therapeutics Inc. are updated in real time on BlackAll Trade.
Perspective Therapeutics Inc. trades at $2.84 (-1.39%). Real-time quotes and charts are available on BlackAll Trade.
Perspective Therapeutics Inc. has a market cap of about $0.44B.
Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and d